Molecular Health Licenses its Proprietary Predictive Analytics to DATEN CAPITAL
- Molecular Health Predict enables highly accurate estimates of clinical trial success probabilities
- Exclusive license for the financial industry granted to DATEN CAPITAL
- Molecular Health to receive an annual license fee and success-based payments
Molecular Health, a leading company in the field of data science for precision medicine and specializing in the development of products and services leveraging its proprietary biomedicine technology platform Dataome®, is pleased to announce that it has granted an exclusive license for Molecular Health Predict (MH Predict) to DATEN CAPITAL LLP (DATEN), for its use in the financial industry. MH Predict was developed by Molecular Health to calculate the likelihood of success of drug clinical trials, and DATEN is a private limited liability partnership founded to commercialize data-science, AI-driven approaches to investing. Molecular Health will receive an annual license fee as well as success-based payments from DATEN.